Revenue Performance - Total revenue for Q1 2025 was $132 million, a 10% increase from $119 million in Q1 2024[3] - Full year 2025 revenue guidance increased from over $600 million to $725-750 million, reflecting a more than 20% increase[5] - Total revenue for the three months ended March 31, 2025, was $132 million, a 10.9% increase from $119 million in the same period of 2024[33] - Total commercial revenue increased to $76 million, up 28.8% from $59 million year-over-year[33] - TRYNGOLZA generated over $6 million in net product sales in its first full quarter following U.S. approval[9] - SPINRAZA generated global sales of $424 million, resulting in royalty revenue of $48 million in Q1 2025[9] - WAINUA achieved sales of $39 million, leading to royalty revenue of $9 million in Q1 2025[9] - Ionis' commercial revenue increased by 28% year-over-year, driven by the launch of TRYNGOLZA and higher royalty revenues[14] Operating Performance - Operating loss on a non-GAAP basis is now expected to be less than $375 million, improved from less than $495 million[5] - Total operating expenses rose to $278 million, an increase of 3.4% compared to $269 million in the same quarter of 2024[33] - The net loss for the quarter was $147 million, compared to a net loss of $143 million in the same quarter of 2024[33] - Non-GAAP net loss was $118 million, compared to $112 million in the same period of the previous year[34] Cash and Investments - Cash, cash equivalents, and short-term investments are projected to be approximately $1.9 billion by year-end 2025[5] - Cash, cash equivalents, and short-term investments decreased to $2,145 million from $2,298 million at the end of December 2024[38] - Total stockholders' equity decreased to $476 million from $588 million at the end of December 2024[38] Research and Development - Donidalorsen is on track for a PDUFA date of August 21, 2025, with positive Phase 2 data showing a 96% reduction in HAE attack rates[9] - ION582 for Angelman syndrome is expected to initiate Phase 3 development in Q2 2025[13] - Key Phase 3 clinical events are expected for Olezarsen and Zilganersen in 2025, with data anticipated to be released[39] Regulatory Approvals - The company achieved regulatory approval for TRYNGOLZA in the EU for FCS and anticipates U.S. approval for Donidalorsen for HAE in 2025[39]

Core Insights - Ionis Pharmaceuticals reported revenue of $132 million for the quarter ended March 2025, reflecting a year-over-year increase of 10.9% and surpassing the Zacks Consensus Estimate of $120.16 million by 9.86% [1] - The company's EPS was -$0.75, an improvement from -$0.98 in the same quarter last year, with an EPS surprise of 32.43% against a consensus estimate of -$1.11 [1] Revenue Breakdown - Commercial revenue from SPINRAZA royalties was $48 million, exceeding the average estimate of $43.02 million by nine analysts, marking a 26.3% increase year over year [4] - Total commercial revenue reached $76 million, surpassing the average estimate of $66.61 million based on eight analysts, representing a 28.8% year-over-year change [4] - Total research and development revenue was $56 million, compared to the average estimate of $50.44 million [4] - WAINUA royalties generated $9 million, slightly below the average estimate of $9.89 million [4] - Other commercial revenue from TEGSEDI and WAYLIVRA was $6 million, falling short of the average estimate of $6.93 million, indicating a 33.3% decline year over year [4] - Collaborative agreement revenue within research and development was $46 million, exceeding the average estimate of $37.10 million, but reflecting a 6.1% decrease year over year [4] Stock Performance - Ionis Pharmaceuticals' shares have returned +9.4% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

分组1 - Ionis Pharmaceuticals reported a quarterly loss of $0.75 per share, better than the Zacks Consensus Estimate of a loss of $1.11, and improved from a loss of $0.98 per share a year ago, representing an earnings surprise of 32.43% [1] - The company posted revenues of $132 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.86%, and compared to year-ago revenues of $119 million [2] - Ionis Pharmaceuticals has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 14.7% since the beginning of the year, while the S&P 500 declined by 5.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $146.33 million, and for the current fiscal year, it is -$3.31 on revenues of $637.57 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 20% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Ionis Pharmaceuticals is a developer of antisense oligonucleotide therapeutic drugs based in Carlsbad, California, and has compelling catalysts expected in 2025/26 [2] Company Overview - The company focuses on both novice and experienced biotech investors, providing insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] Analyst Background - The analysis is led by a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, having prepared detailed reports on over 1,000 companies [2]

Ionis Pharmaceuticals (IONS) shares rallied 8.9% in the last trading session to close at $27.77. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 22.8% loss over the past four weeks.The rise in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries.This drug discovery and development company is expected to post quarterly loss of $1.07 per share ...

Ionis Pharmaceuticals (IONS) signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive rights to market its wholly owned drug Tryngolza outside the United States (except Canada and China).The FDA recently approved Tryngolzafor treating familial chylomicronemia syndrome (FCS), a rare genetic disease marked by extremely elevated triglyceride levels. This nod makes the drug the first approved treatment for FCS in the country. Italso marks Ionis’ first independent commercial ...

Core Insights - Praxis Precision Medicines, Inc. is set to present data from four late-stage programs focused on epilepsy and movement disorders at the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5 to 9, 2025 in San Diego, California [1] Company Overview - Praxis is a clinical-stage biopharmaceutical company that translates genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [11] - The company has developed a diversified, multimodal CNS portfolio, including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates [11] Pipeline and Clinical Programs - The company is advancing its innovative pipeline with four late-stage programs that aim to transform patient care [2] - Key clinical updates will be presented from the vormatrigine ENERGY program, along with newly initiated clinical trials enrolling patients across the U.S., Europe, and Latin America [2] - Praxis will host an In-Booth Speaker Showcase featuring experts in the field, aimed at sharing their mission to revolutionize therapies for CNS disorders [2] Presentation Details - Praxis will present multiple poster presentations at the AAN, including: - P5-011: Focus on Essential Tremor Management and Impact, featuring results from an online survey capturing healthcare provider and patient perspectives [3] - P5-012: Characteristics of Adult Essential Tremor Patients in a Decentralized US Clinical Trial [3] - P9-012: An observational study on epilepsy monitoring to better understand the patient journey [4] - P4-006: Updates from the first-in-human Phase 1 clinical trial evaluating the safety and tolerability of vormatrigine [5] Product Highlights - Relutrigine (PRAX-562) is a first-in-class small molecule targeting developmental and epileptic encephalopathies (DEEs), showing promise in preclinical studies for seizure control [6][7] - Vormatrigine (PRAX-628) is a next-generation small molecule for adult focal onset seizures and generalized epilepsy, demonstrating superior selectivity and potency in preclinical models [8] - Elsunersen (PRAX-222) is an antisense oligonucleotide targeting SCN2A gene expression, showing significant seizure reduction in clinical studies [9] - Ulixacaltamide is a selective small molecule inhibitor of T-type calcium channels, currently in development for essential tremor [10]

Core Viewpoint - Ionis Pharmaceuticals reported a narrower loss per share for Q4 2024 compared to estimates, with total revenues exceeding expectations but declining year-over-year Financial Performance - Ionis incurred a loss of 66 cents per share in Q4 2024, better than the Zacks Consensus Estimate of a loss of $1.12 per share [1] - Total revenues for Q4 were $227 million, surpassing the Zacks Consensus Estimate of $137.5 million, but down 30.2% year-over-year [2] - For the full year 2024, Ionis reported a loss of $3.04 per share, which was narrower than the Zacks Consensus Estimate of a loss of $3.47 per share, with total revenues of $705 million, beating the estimate of $618.6 million [12] Revenue Breakdown - Commercial revenues in Q4 were $86 million, up 8.9% year-over-year, exceeding the Zacks Consensus Estimate of $81 million [7] - Spinraza royalties contributed $64 million to commercial revenues, up 1.6% year-over-year, with Spinraza sales recorded at $421.4 million, up 2% year-over-year [8] - Wainua generated $10 million in royalty revenues, with sales of $42 million in Q4, reflecting an 84% sequential increase [8] - R&D revenues declined 42.7% year-over-year to $141 million, but still beat the Zacks Consensus Estimate of $57 million [10] Cost Management - Adjusted operating costs decreased by 1.3% year-over-year to $301 million in Q4, while SG&A costs rose 18.5% to support new product launches [11] Future Guidance - Ionis expects total revenues to exceed $600 million in 2025, with a shift towards increasing commercial revenues [13] - The company anticipates an adjusted operating loss of less than $495 million and expects SG&A costs to rise due to investments in marketing activities [14] Product Development Updates - Ionis' first wholly-owned drug, Tryngolza, was approved by the FDA in December 2024 for a rare disease, with a marketing application under review in the EU [6] - Olezarsen is being evaluated in late-stage studies for severe hypertriglyceridemia, with data expected in the second half of 2025 [15] - Donidalorsen is under FDA review for hereditary angioedema, with a decision expected on August 21, 2025 [16] - AstraZeneca and Ionis are developing Wainua for another form of amyloidosis, with data from a phase III study expected in the second half of 2026 [18]

Financial Data and Key Metrics Changes - Ionis Pharmaceuticals reported a non-GAAP operating loss of $345 million, which is a significant improvement compared to the 2024 guidance [48] - The company exceeded its 2024 revenue guidance by more than $130 million, earning revenues of $705 million last year [48] - SPINRAZA remained the primary source of commercial revenue, generating $216 million in royalties for the year [48] Business Line Data and Key Metrics Changes - WAYLIVRA product revenue achieved an 84% increase in the fourth quarter compared to the third quarter, with total sales of $85 million for the year [49][50] - The new-to-brand share for WAYLIVRA is approximately 40%, indicating strong demand and growth in the ATTR polyneuropathy market [75] - Tringolza, the first independent launch, is expected to gradually build momentum, with several hundred patients currently identified and in the process of being diagnosed and treated [104][105] Market Data and Key Metrics Changes - The total addressable US FCS patient population is estimated to be up to approximately 3,000 people, with a significant portion still unidentified and undiagnosed [15] - The company is actively working to increase awareness and diagnosis of FCS through healthcare provider education [16] - The SHTG patient population is significantly larger, with the company planning to scale its commercial organization to address this market [21] Company Strategy and Development Direction - Ionis Pharmaceuticals aims to deliver three additional independent launches over the next three years, including Donidalorsen and Zilganersen, which represent multibillion-dollar revenue potential [9] - The company is focused on maximizing the value of its innovative medicines while maintaining strong operating leverage [51] - Ionis is positioned to achieve substantial and sustained revenue growth and positive cash flow through its expanding pipeline and commercial efforts [59][60] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing launch of Tringolza and the potential for future launches, emphasizing the importance of patient identification and physician engagement [15][104] - The company anticipates a gradual buildup of launch momentum for Tringolza, especially in the first few quarters [52] - Management highlighted the potential for olezarsen to become the standard of care for both FCS and SHTG, based on positive clinical data [38] Other Important Information - The company has a rich pipeline with multiple late-stage data readouts and regulatory actions expected this year and next [32] - Ionis Pharmaceuticals has retained global rights for its alpha-synuclein and LRRK2 programs, indicating a strong commitment to advancing these therapies [94] Q&A Session Summary Question: Insights on olezarsen and SHTG - Management clarified that the ESSENCE study is a safety study and not directly targeting the commercial patient population, but it will provide important safety read-throughs for SHTG [68][70] Question: ATTR polyneuropathy market performance - Management reported that WAYLIVRA has captured about 40% of new patient starts, with strong demand and growth observed [75][76] Question: Design for SHTG phase three study - Management explained that the CORE studies are well-powered for triglyceride reductions, and while acute pancreatitis events are not the primary focus, they expect to see meaningful signals based on previous data [81][82] Question: Growth drivers for WAYLIVRA - Management noted that the majority of growth is driven by new patient starts, with a strong emphasis on self-administration and affordability contributing to the uptake [91][92] Question: Tringolza launch metrics - Management indicated that several hundred patients have been identified and are in the process of being diagnosed, with a focus on expediting the prescription process [104][105]

Financial Performance - Total revenue for 2024 was $705.1 million, a decrease of 10.5% from $787.6 million in 2023[376] - The company recorded a net loss of $453.9 million in 2024, compared to a net loss of $366.3 million in 2023, indicating an increase of about 23.9%[412] - The income tax benefit for 2024 was $6.2 million, a significant improvement from an income tax expense of $32.3 million in 2023[409] - Investment income increased from $89.0 million in 2023 to $107.0 million in 2024, a growth of about 20.2% driven by higher interest rates[403] - Interest expense increased from $12.7 million in 2023 to $17.0 million in 2024, representing a rise of approximately 33.9% due to new convertible notes[404] Operating Expenses - Total operating expenses increased to $1,180.2 million in 2024 from $1,141.4 million in 2023, resulting in a loss from operations of $475.1 million[376] - Non-cash compensation expense related to equity awards increased to $130.2 million in 2024 from $105.7 million in 2023, driven by higher headcount and stock prices[384] - SG&A expenses rose from $232.6 million in 2023 to $267.5 million in 2024, marking an increase of approximately 15% due to new product launches[402] - Medical affairs expenses increased to $31.9 million in 2024 from $22.9 million in 2023, reflecting advancements in the late-stage pipeline[396] - Total R&D support expenses increased from $96.0 million in 2023 to $101.2 million in 2024, reflecting a rise of about 6.3%[400] Revenue Sources - SPINRAZA royalties decreased to $216.1 million in 2024 from $240.4 million in 2023, impacted by a non-recurring annual order from a single country[378] - WAINUA joint development revenue decreased to $79.4 million in 2024 from $126.4 million in 2023, primarily due to winding down development activities[382] - The company launched WAINUA in the U.S. in late January 2024 and TRYNGOLZA in late December 2024, contributing to new commercial revenue sources[378] - R&D revenue is recognized from various collaboration agreements, including upfront payments, milestone payments, and license fees, requiring significant estimates and judgments[432] - Revenue from R&D services is recognized based on an input method estimating total costs to complete performance obligations, which may require adjustments if estimates change[433] Cash and Investments - Cash, cash equivalents, and short-term investments were $2,297.7 million as of December 31, 2024, down from $2,331.2 million in 2023[376] - The company raised approximately $489 million from a public stock offering in September 2024, contributing to increased cash available for investments[403] Development Costs - Total drug development expenses were $568.5 million in 2024, compared to $564.8 million in 2023, indicating stable development costs[392] - Manufacturing and development chemistry expenses decreased from $74.1 million in 2023 to $67.1 million in 2024, a reduction of approximately 9.4%[398] - As of December 31, 2024, a hypothetical 10% increase in liability for preclinical and clinical development costs would increase loss before income tax benefit by approximately $7.7 million[436] - The company maintains an accrual for preclinical and clinical development costs, estimating liabilities based on contracted fees and expected expenses[435] Future Estimates and Risks - Factors affecting future royalty payments include regulatory approvals and competition, which could lead to significant changes in revenue estimates[439] - The allocation of transaction price to performance obligations involves estimating relative stand-alone selling prices, which may require significant judgments[431] - The company assesses the propriety of revenue recognition and deferred revenue, along with estimating future royalty payments under its royalty purchase agreement[430] - The company recognizes revenue related to milestone payments based on the probability of achievement and the estimated period of performance[437] - In 2023, the company entered into a royalty purchase agreement with Royalty Pharma to monetize future royalties from SPINRAZA and pelacarsen, with estimates subject to change based on sales performance[438] Contractual Obligations - Total contractual obligations as of December 31, 2024, amounted to $1,513.4 million, with $31.6 million due within one year[417] - The company does not utilize derivative financial instruments to manage exposure to interest rate changes, believing it is not subject to material risks from such changes as of December 31, 2024[440] Historical Performance - The company has generated approximately $7.9 billion in revenue since its inception through December 31, 2024[413]